Safety Evaluation of Telmisartan Plus Hydrochlorothiazide in Patients With Mild-to-Moderate Hypertension
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to assess the safety of six month of open-label, treatment with the fixed dose
combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 mg in a subset of patients
with mild-to-moderate hypertension who completed the eight week randomized, double blind
502.261 study.
Phase:
Phase 3
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Hydrochlorothiazide Telmisartan Telmisartan, hydrochlorothiazide drug combination